Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials)

详细信息    查看全文

• 作者：Lori Mosca ; MD ; MPH ; PhD^a ; ^{ljm10@columbia.edu} ; Christie M. Ballantyne ; MD^b ; Harold E. Bays ; MD^c ; John R. Guyton ; MD^d ; Sephy Philip ; RPh ; PharmD^e ; Ralph T. Doyle Jr. ; BA^e ; Rebecca A. Juliano ; PhD^e
• 刊名：The American Journal of Cardiology
• 出版年：2017
• 出版时间：1 February 2017
• 年：2017
• 卷：119
• 期：3
• 页码：397-403
• 全文大小：228 K
• 卷排序：119

文摘

There are limited data on the efficacy and safety of triglyceride (TG)-lowering agents in women. We conducted subgroup analyses of the effects of icosapent ethyl (a high-purity prescription form of the ethyl ester of the omega-3 fatty acid, eicosapentaenoic acid) on TG levels (primary efficacy variable) and other atherogenic and inflammatory parameters in a total of 215 women with a broad range of TG levels (200–2000 mg/dl) enrolled in two 12-week placebo-controlled trials: MARINE (n = 18; placebo, n = 18) and ANCHOR (n = 91; placebo, n = 88). Icosapent ethyl 4 g/day significantly reduced TG levels from baseline to week 12 versus placebo in both MARINE (−22.7%; p = 0.0327) and ANCHOR (−21.5%; p <0.0001) without increasing low-density lipoprotein cholesterol levels. Significant improvements were also observed in non–high-density lipoprotein cholesterol levels in MARINE (−15.7%; p = 0.0082) and ANCHOR (−14.2%; p <0.0001) and total cholesterol levels in MARINE (−14.9%; p = 0.0023) and ANCHOR (−12.1%; p <0.0001), along with significant increases of >500% in eicosapentaenoic acid levels in plasma and red blood cells (all p <0.001). Icosapent ethyl was well tolerated, with adverse-event profiles comparable with findings in the overall studies. In conclusion, icosapent ethyl 4 g/day significantly reduced TG levels and other atherogenic parameters in women without increasing low-density lipoprotein cholesterol levels compared with placebo; the clinical implications of these findings are being evaluated in the REDUCtion of Cardiovascular Events With Eicosapentaenoic Acid [EPA]–Intervention Trial (REDUCE-IT) cardiovascular outcomes study.